טוען...
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF(V600E) targeted inhibition in a novel syngeneic murine glioma model
Inhibitors of BRAF(V600E) kinase are currently under investigations in preclinical and clinical studies involving BRAF(V600E) glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients tumors continue to grow despite treatment....
שמור ב:
הוצא לאור ב: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Impact Journals LLC
2016
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342782/ https://ncbi.nlm.nih.gov/pubmed/27713119 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12419 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|